Paxlovid Rebound: Why COVID-19 Symptoms Can Return After Treatment

You take a course of Paxlovid, start feeling better, test negative and get on with life, only for symptoms to return a few days later, sometimes alongside a positive test again. This pattern, known as COVID-19 rebound, has become a well-documented, if still not fully understood, part of the antiviral treatment picture.

What exactly is Paxlovid rebound?

Rebound refers to a recurrence of COVID-19 symptoms, a new positive viral test after having tested negative, or both, typically occurring between two and eight days after someone appeared to have recovered. It's specifically associated with Paxlovid (nirmatrelvir plus ritonavir), though it isn't exclusive to it and understanding the pattern can help you recognise it for what it is rather than assuming something has gone seriously wrong with your treatment.

How common is it really?

Estimates of how often rebound occurs vary between studies, generally landing somewhere around 3% to 5% of people who take Paxlovid or molnupiravir, another oral antiviral used for COVID-19. Interestingly, some research has found rebound occurring at broadly similar rates in people who received a placebo during clinical trials, which points to an important, sometimes overlooked fact about this phenomenon.

Is rebound actually caused by the medication?

This is one of the more genuinely surprising findings in the research so far. A brief return of symptoms appears to be part of the natural course of SARS-CoV-2 infection for some people, independent of whether they took Paxlovid at all and regardless of their vaccination status. This doesn't mean Paxlovid definitely has no relationship to rebound, but it does mean rebound isn't simply a side effect unique to the drug and it happens to some people who never took any antiviral treatment in the first place.

How severe is rebound compared with the original illness?

When rebound does occur, it tends to be considerably milder than the initial infection for most people. It's generally described as a brief, self-limited recurrence rather than a return to the same severity as the original illness, though individual experiences do vary and some people find the returning symptoms more bothersome than others.

Are you contagious again during rebound?

Yes and this is one of the most practically important things to know. If your symptoms return, or you test positive again after a period of testing negative, you should treat this as a fresh infectious period and isolate again accordingly, following the same precautions you would during your original illness. This matters particularly if you'd already returned to work, school or normal social contact, assuming you were fully in the clear.

Should rebound change how you think about taking Paxlovid?

Not really and it's worth keeping this in proportion. Paxlovid remains a well-established, effective treatment for reducing the risk of hospitalisation in eligible high-risk patients and the possibility of rebound, while worth knowing about in advance, isn't a strong reason to decline treatment if you're eligible and your doctor recommends it. The benefit of reduced hospitalisation risk for high-risk patients generally outweighs the inconvenience of a possible, typically mild, rebound period.

Who is currently eligible for Paxlovid in the UK?

Eligibility has broadened over time as evidence and guidance have developed. As of 2026, NHS guidance covers a wider group than in the earliest phase of antiviral rollout, including adults aged 85 and over, care home residents aged 70 and over and people with specific conditions such as end-stage heart failure or those on an organ transplant waiting list, alongside other risk groups including certain people with diabetes, obesity or heart failure. Because eligibility criteria can be updated, checking current NHS guidance or discussing your own risk factors with a healthcare professional is the most reliable way to know whether you qualify.

How treatment access has changed

Many local health systems have shifted responsibility for accessing antiviral treatment onto patients themselves rather than automatically contacting everyone who reports a positive test, often through an online self-referral portal specific to your local health board or integrated care system. If you believe you're eligible and test positive, acting promptly matters, since Paxlovid needs to be started within the first five days of symptoms to be effective, which leaves a narrower window than many people expect.

What to do if you experience rebound

If your symptoms return or you test positive again after finishing a course of Paxlovid, the general approach mirrors managing the original infection: isolate again, monitor for any warning signs that would warrant medical attention and rest while the second, typically milder, phase resolves. There's generally no need for a repeat course of Paxlovid for rebound specifically, though contacting a doctor is reasonable if your symptoms are more than mild or you're unsure how to interpret what's happening.

Why rebound gets more attention than it perhaps deserves

Part of why rebound became such a widely discussed phenomenon is that it happened to several high-profile public figures early in Paxlovid's rollout, which brought it considerably more media attention than a similarly common side effect of most other medications would typically receive. This visibility has been useful in one sense, since it means most people now know what rebound is and don't panic if it happens to them, but it's also occasionally led to an inflated sense of how disruptive or dangerous rebound actually tends to be for the average person who experiences it.

Keeping this in perspective matters when weighing up whether to take Paxlovid if you're eligible. A well-understood, generally mild possibility of symptoms returning for a few extra days is a fundamentally different consideration to a serious side effect and treating it as the latter risks discouraging eligible high-risk patients from a treatment that meaningfully reduces their chance of hospitalisation.

A quick recap

Paxlovid rebound, a return of symptoms or a positive test days after apparent recovery, affects an estimated 3% to 5% of people who take the drug, though similar rebound patterns have also been observed in people who received no antiviral treatment at all. Rebound is typically mild, means you're contagious again and shouldn't generally discourage eligible high-risk patients from taking Paxlovid, given its established benefit in reducing hospitalisation risk.

Frequently asked questions

Do I need another course of Paxlovid if I experience rebound?

Generally no, rebound doesn't typically require repeat antiviral treatment, though contacting a doctor is reasonable if symptoms are significant or you're uncertain how to manage the situation.

How long does Paxlovid rebound usually last?

Rebound episodes tend to be brief and self-limited, generally resolving within several days, similar to a shorter, milder version of the original illness.

Can rebound happen if I didn't take Paxlovid?

Yes, research suggests a brief return of symptoms can occur as part of the natural course of COVID-19 infection in some people regardless of whether they took an antiviral treatment.

Should I avoid Paxlovid because of the risk of rebound?

Not generally, since rebound is typically mild and the established benefit of Paxlovid in reducing hospitalisation risk for eligible high-risk patients usually outweighs this consideration.

How do I know if I'm eligible for Paxlovid in the UK?

Current NHS guidance covers specific age and risk groups and checking the latest eligibility criteria or speaking with a healthcare professional is the most reliable way to confirm whether you qualify.